RU2014105513A - Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом - Google Patents
Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом Download PDFInfo
- Publication number
- RU2014105513A RU2014105513A RU2014105513/04A RU2014105513A RU2014105513A RU 2014105513 A RU2014105513 A RU 2014105513A RU 2014105513/04 A RU2014105513/04 A RU 2014105513/04A RU 2014105513 A RU2014105513 A RU 2014105513A RU 2014105513 A RU2014105513 A RU 2014105513A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- seq
- subject
- fibrosis
- disease
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 21
- 206010016654 Fibrosis Diseases 0.000 title claims abstract 7
- 230000004761 fibrosis Effects 0.000 title claims abstract 6
- 230000002300 anti-fibrosis Effects 0.000 title 1
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 8
- 208000035475 disorder Diseases 0.000 claims abstract 8
- 230000037396 body weight Effects 0.000 claims abstract 4
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract 4
- 239000003937 drug carrier Substances 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims abstract 2
- 206010039710 Scleroderma Diseases 0.000 claims abstract 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims abstract 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims abstract 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims abstract 2
- 201000008383 nephritis Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 230000009787 cardiac fibrosis Effects 0.000 abstract 1
- 230000007882 cirrhosis Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161509340P | 2011-07-19 | 2011-07-19 | |
| US61/509,340 | 2011-07-19 | ||
| US201261662337P | 2012-06-20 | 2012-06-20 | |
| US61/662,337 | 2012-06-20 | ||
| PCT/US2012/047468 WO2013013085A2 (en) | 2011-07-19 | 2012-07-19 | Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014105513A true RU2014105513A (ru) | 2015-08-27 |
Family
ID=47558730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014105513/04A RU2014105513A (ru) | 2011-07-19 | 2012-07-19 | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20140057831A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2734220A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014527040A (cg-RX-API-DMAC7.html) |
| CN (2) | CN103890003B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012283924A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014001268A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2842330A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1198333A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL230510A0 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014105513A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013013085A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170232276A1 (en) * | 2014-09-30 | 2017-08-17 | Primegen Biotech, Llc | Treatment of fibrosis using deep tissue heating and stem cell therapy |
| US20160137714A1 (en) * | 2014-11-12 | 2016-05-19 | Thrasos Innovation, Inc. | Peptides with enhanced stability and their use in methods for treating diseases |
| EP3289073A4 (en) * | 2015-05-01 | 2019-07-17 | University of Miami | METHOD AND COMPOSITIONS FOR THE CONVERSION OF NON-ENDOCRINE PANCREATIC TISSUE IN INSULIN-PRODUCING CELLS |
| AU2016260190A1 (en) * | 2015-05-12 | 2017-11-23 | The Regents Of The University Of California | Peptide treatment for inflammation and fibrosis |
| BR112017026209A2 (pt) * | 2015-06-05 | 2018-11-27 | Ibio, Inc. | fragmentos e variantes de endostatinas para uso no tratamento de fibrose |
| WO2019133950A1 (en) * | 2017-12-30 | 2019-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Smad7 for treatment and prevention of posterior capsule opacification |
| ES2906715T3 (es) * | 2018-09-06 | 2022-04-20 | Marine Essence Biosciences Corp Of Usa | Dispositivos de biomaterial para la regeneración de tejidos guiada |
| WO2020086580A1 (en) * | 2018-10-22 | 2020-04-30 | Carlson William D | Therapeutic combinations of tdfrps and additional agents and methods of use |
| WO2021007094A1 (en) * | 2019-07-10 | 2021-01-14 | Musc Foundation For Research Development | Endostatin peptides for the treatment of tumors, fibrosis and acute lung injury |
| CN111704653B (zh) * | 2020-06-08 | 2023-10-03 | 深圳市图微安创科技开发有限公司 | 靶向于纤连蛋白衍生肽的抑制剂多肽化合物及其用途 |
| WO2022197855A1 (en) * | 2021-03-16 | 2022-09-22 | Therapeutics By Design, LLC | Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis |
| CN113069531B (zh) * | 2021-04-09 | 2023-02-28 | 南开大学 | 一种防疤痕皮肤创伤修复用水凝胶及其制备方法 |
| CN116768974A (zh) * | 2022-03-11 | 2023-09-19 | 中山大学 | 用于预防和/或治疗肾纤维化的多肽化合物 |
| WO2024081245A1 (en) | 2022-10-10 | 2024-04-18 | Therapeutics By Design, LLC | Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997034618A1 (en) * | 1996-03-22 | 1997-09-25 | The General Hospital Corporation | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| WO2003106656A2 (en) * | 2002-06-17 | 2003-12-24 | Thrasos, Inc. | Single domain tdf-related compounds and analogs thereof |
| EP2319526A1 (en) * | 2004-06-17 | 2011-05-11 | Thrasos Therapeutics, Inc. | Tdf-related compounds and analogs thereof |
| US8299212B2 (en) * | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
| WO2010082903A1 (en) * | 2009-01-16 | 2010-07-22 | Agency For Science, Technology And Research | Method of inhibiting proliferation of hepatic stellate cells |
| EP2401614A1 (en) * | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| WO2010128158A1 (en) * | 2009-05-08 | 2010-11-11 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
-
2012
- 2012-07-19 WO PCT/US2012/047468 patent/WO2013013085A2/en not_active Ceased
- 2012-07-19 AU AU2012283924A patent/AU2012283924A1/en not_active Abandoned
- 2012-07-19 US US13/553,685 patent/US20140057831A1/en not_active Abandoned
- 2012-07-19 CA CA2842330A patent/CA2842330A1/en not_active Abandoned
- 2012-07-19 JP JP2014521801A patent/JP2014527040A/ja active Pending
- 2012-07-19 EP EP12814119.9A patent/EP2734220A4/en not_active Withdrawn
- 2012-07-19 BR BR112014001268A patent/BR112014001268A2/pt not_active IP Right Cessation
- 2012-07-19 CN CN201280045650.7A patent/CN103890003B/zh not_active Expired - Fee Related
- 2012-07-19 HK HK14111848.5A patent/HK1198333A1/zh unknown
- 2012-07-19 RU RU2014105513/04A patent/RU2014105513A/ru not_active Application Discontinuation
- 2012-07-19 CN CN201610543024.0A patent/CN106478776A/zh active Pending
-
2014
- 2014-01-16 IL IL230510A patent/IL230510A0/en unknown
-
2015
- 2015-08-05 US US14/818,652 patent/US20160058829A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013013085A3 (en) | 2014-03-13 |
| EP2734220A2 (en) | 2014-05-28 |
| IL230510A0 (en) | 2014-03-31 |
| US20160058829A1 (en) | 2016-03-03 |
| JP2014527040A (ja) | 2014-10-09 |
| AU2012283924A1 (en) | 2014-02-06 |
| BR112014001268A2 (pt) | 2017-02-21 |
| CN103890003B (zh) | 2016-08-24 |
| US20140057831A1 (en) | 2014-02-27 |
| CN103890003A (zh) | 2014-06-25 |
| EP2734220A4 (en) | 2015-01-21 |
| CA2842330A1 (en) | 2013-01-24 |
| HK1198333A1 (zh) | 2015-04-02 |
| CN106478776A (zh) | 2017-03-08 |
| WO2013013085A2 (en) | 2013-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014105513A (ru) | Противофиброзные пептиды и их применение в способах лечения заболеваний и расстройств, характеризующихся фиброзом | |
| JP2014527040A5 (cg-RX-API-DMAC7.html) | ||
| EP3579833B1 (en) | Methods of treating influenza | |
| JP2021121605A (ja) | Ａｓｃの発現、ｎｌｒｐ３の発現、及び／又はｎｌｒｐ３インフラマソーム複合体の形成を阻害するためのジアセレイン又はそのアナログ | |
| JP5255456B2 (ja) | ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法 | |
| CL2011000353A1 (es) | Compuestos derivados de 1-{4-[metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino]ciclohexil}metanosulfonamida o una sal farmaceuticamente aceptable; forma cristalina de la sal maleato; procedimiento de preparacion; composicion farmaceutica; y uso para tratar enfermedades alergicas, cancer, lupus. | |
| BR112014010228A8 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
| JP2015518818A5 (cg-RX-API-DMAC7.html) | ||
| RU2019123160A (ru) | Способ модуляции активности инфламмасом и воспаления в легком | |
| JP2013520405A5 (cg-RX-API-DMAC7.html) | ||
| JP2023081969A (ja) | Ｔｌｒアゴニストによる呼吸器感染症の治療 | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| RU2015101276A (ru) | Способы лечения болезней и композиции для их осуществления | |
| JP2015517488A5 (cg-RX-API-DMAC7.html) | ||
| EP3728289B1 (en) | Optimised compounds | |
| EA201201114A1 (ru) | Агонистические dr5-связывающие полипептиды | |
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| MX2012010161A (es) | Metodo para tratar el mal de parkinson. | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| US20130172414A1 (en) | Pharmaceutical composition comprising levocarnitine and dobesilate | |
| JP2016508123A5 (cg-RX-API-DMAC7.html) | ||
| JP2018538306A5 (cg-RX-API-DMAC7.html) | ||
| RU2014124171A (ru) | Лекарственное средство для терапевтического лечения и/или улучшения состояния при сепсисе | |
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2016513124A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161128 |